How can nanotechnology help membrane vesicle-based cancer immunotherapy development?

References

• Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9:581 - 93; http://dx.doi.org/10.1038/nri2567; PMID: 19498381
   PubMed Web of Science ®Google Scholar
• Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983; 97:329 - 39; http://dx.doi.org/10.1083/jcb.97.2.329; PMID: 6309857
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594 - 600; http://dx.doi.org/10.1038/nm0598-594; PMID: 9585234
   PubMed Web of Science ®Google Scholar
• Zhu MT, Li YY, Shi J, Feng WY, Nie GJ, Zhao YL. Exosomes as extrapulmonary signaling conveyors for nanoparticle-induced systemic immune activation. Small 2012; 8:404 - 12; http://dx.doi.org/10.1002/smll.201101708; PMID: 22144073
   PubMed Web of Science ®Google Scholar
• Zhu MT, Tian X, Song X, Li YY, Tian YH, Zhao YL, et al. Nanoparticle-induced exosomes target antigen-presenting cells to initiate Th1-type immune activation. Small 2012; 8:2841 - 8; http://dx.doi.org/10.1002/smll.201200381; PMID: 22674628
   PubMed Web of Science ®Google Scholar
• Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3:1156 - 62; http://dx.doi.org/10.1038/ni854; PMID: 12426563
   PubMed Web of Science ®Google Scholar
• André F, Chaput N, Schartz NEC, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172:2126 - 36; PMID: 14764678
   PubMed Web of Science ®Google Scholar
• Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS ONE 2009; 4:e4942; http://dx.doi.org/10.1371/journal.pone.0004942; PMID: 19319200
   PubMed Web of Science ®Google Scholar
• Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 2005; 3:10; http://dx.doi.org/10.1186/1479-5876-3-10; PMID: 15740633
   PubMed Web of Science ®Google Scholar
• Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005; 3:9; http://dx.doi.org/10.1186/1479-5876-3-9; PMID: 15723705
   PubMed Web of Science ®Google Scholar
• Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what’s next?. Cancer Res 2010; 70:1281 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276; PMID: 20145139
   PubMed Web of Science ®Google Scholar
• Yang YS, Xiu FM, Cai ZJ, Wang JL, Wang QQ, Fu YX, et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 2007; 133:389 - 99; http://dx.doi.org/10.1007/s00432-006-0184-7; PMID: 17219198
   PubMed Web of Science ®Google Scholar
• Xie YF, Bai O, Zhang HF, Yuan JY, Zong S, Chibbar R, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. J Cell Mol Med 2010; 14:2655 - 66; http://dx.doi.org/10.1111/j.1582-4934.2009.00851.x; PMID: 19627400
   PubMed Web of Science ®Google Scholar
• Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172:2137 - 46; PMID: 14764679
   PubMed Web of Science ®Google Scholar
• Tian X, Zhu MT, Tian YH, Ramm GA, Zhao YL, Nie GJ. A membrane vesicle-based dual vaccine against melanoma and Lewis lung carcinoma. Biomaterials 2012; 33:6147 - 54; http://dx.doi.org/10.1016/j.biomaterials.2012.05.034; PMID: 22681975
   PubMed Web of Science ®Google Scholar
• van den Boorn JG, Schlee M, Coch C, Hartmann G. SiRNA delivery with exosome nanoparticles. Nat Biotechnol 2011; 29:325 - 6; http://dx.doi.org/10.1038/nbt.1830; PMID: 21478846
   PubMed Web of Science ®Google Scholar
• Shi JJ, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010; 10:3223 - 30; http://dx.doi.org/10.1021/nl102184c; PMID: 20726522
   PubMed Web of Science ®Google Scholar
• Miao QH, Xu DX, Wang Z, Xu L, Wang TM, Wu Y, et al. Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials 2010; 31:7364 - 75; http://dx.doi.org/10.1016/j.biomaterials.2010.06.012; PMID: 20599267
   PubMed Web of Science ®Google Scholar
• Miao QH, Li SP, Han SY, Wang Z, Wu Y, Nie GJ. Construction of hydroxypropyl-β-cyclodextrin copolymer nanoparticles and targeting delivery of paclitaxel. J Nanopart Res 2012; 14:1043 - 56; http://dx.doi.org/10.1007/s11051-012-1043-x
   Web of Science ®Google Scholar
• Alvarez-Erviti L, Seow Y, Yin HF, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29:341 - 5; http://dx.doi.org/10.1038/nbt.1807; PMID: 21423189
   PubMed Web of Science ®Google Scholar
• Zhuang XY, Xiang XY, Grizzle W, Sun DM, Zhang SQ, Axtell RC, et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011; 19:1769 - 79; http://dx.doi.org/10.1038/mt.2011.164; PMID: 21915101
   PubMed Web of Science ®Google Scholar
• Smith AM, Nie SM. Next-generation quantum dots. Nat Biotechnol 2009; 27:732 - 3; http://dx.doi.org/10.1038/nbt0809-732; PMID: 19668181
   PubMed Web of Science ®Google Scholar
• Sun CJ, Yang H, Yuan Y, Tian X, Wang LM, Guo Y, et al. Controlling assembly of paired gold clusters within apoferritin nanoreactor for in vivo kidney targeting and biomedical imaging. J Am Chem Soc 2011; 133:8617 - 24; http://dx.doi.org/10.1021/ja200746p; PMID: 21542609
   PubMed Web of Science ®Google Scholar
• Sinyakov MS, Dror M, Lublin-Tennenbaum T, Salzberg S, Margel S, Avtalion RR. Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies. Vaccine 2006; 24:6534 - 41; http://dx.doi.org/10.1016/j.vaccine.2006.06.021; PMID: 16842893
   PubMed Web of Science ®Google Scholar
• Xu LG, Liu Y, Chen ZY, Li W, Liu Y, Wang LM, et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett 2012; 12:2003 - 12; http://dx.doi.org/10.1021/nl300027p; PMID: 22372996
   PubMed Web of Science ®Google Scholar
• Meng J, Meng J, Duan JH, Kong H, Li L, Wang C, et al. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an anti-tumor immunotherapy. Small 2008; 4:1363 - 70; http://dx.doi.org/10.1002/smll.200701059
   Web of Science ®Google Scholar